Copyright Reports & Markets. All rights reserved.

Global Neuroendocrine Tumor Drug Market Professional Survey Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Industry Overview of Neuroendocrine Tumor Drug

      • 1.1 Definition of Neuroendocrine Tumor Drug
      • 1.2 Neuroendocrine Tumor Drug Segment by Type
        • 1.2.1 Global Neuroendocrine Tumor Drug Production Growth Rate Comparison by Types (2014-2025)
        • 1.2.2 mTOR protein inhibitors
        • 1.2.3 Tyrosine kinase 3 inhibitors
        • 1.2.4 Somatostatin receptor antagonists
        • 1.2.5 Growth hormone releasing factor antagonists
        • 1.2.6 Somatostatin receptor agonists
        • 1.2.7 Others
      • 1.3 Neuroendocrine Tumor Drug Segment by Applications
        • 1.3.1 Global Neuroendocrine Tumor Drug Consumption Comparison by Applications (2014-2025)
        • 1.3.2 Hospital
        • 1.3.3 Clinic
        • 1.3.4 Others
      • 1.4 Global Neuroendocrine Tumor Drug Overall Market
        • 1.4.1 Global Neuroendocrine Tumor Drug Revenue (2014-2025)
        • 1.4.2 Global Neuroendocrine Tumor Drug Production (2014-2025)
        • 1.4.3 North America Neuroendocrine Tumor Drug Status and Prospect (2014-2025)
        • 1.4.4 Europe Neuroendocrine Tumor Drug Status and Prospect (2014-2025)
        • 1.4.5 China Neuroendocrine Tumor Drug Status and Prospect (2014-2025)
        • 1.4.6 Japan Neuroendocrine Tumor Drug Status and Prospect (2014-2025)
        • 1.4.7 Southeast Asia Neuroendocrine Tumor Drug Status and Prospect (2014-2025)
        • 1.4.8 India Neuroendocrine Tumor Drug Status and Prospect (2014-2025)

      2 Manufacturing Cost Structure Analysis

      • 2.1 Raw Material and Suppliers
      • 2.2 Manufacturing Cost Structure Analysis of Neuroendocrine Tumor Drug
      • 2.3 Manufacturing Process Analysis of Neuroendocrine Tumor Drug
      • 2.4 Industry Chain Structure of Neuroendocrine Tumor Drug

      3 Development and Manufacturing Plants Analysis of Neuroendocrine Tumor Drug

      • 3.1 Capacity and Commercial Production Date
      • 3.2 Global Neuroendocrine Tumor Drug Manufacturing Plants Distribution
      • 3.3 Major Manufacturers Technology Source and Market Position of Neuroendocrine Tumor Drug
      • 3.4 Recent Development and Expansion Plans

      4 Key Figures of Major Manufacturers

      • 4.1 Neuroendocrine Tumor Drug Production and Capacity Analysis
      • 4.2 Neuroendocrine Tumor Drug Revenue Analysis
      • 4.3 Neuroendocrine Tumor Drug Price Analysis
      • 4.4 Market Concentration Degree

      5 Neuroendocrine Tumor Drug Regional Market Analysis

      • 5.1 Neuroendocrine Tumor Drug Production by Regions
        • 5.1.1 Global Neuroendocrine Tumor Drug Production by Regions
        • 5.1.2 Global Neuroendocrine Tumor Drug Revenue by Regions
      • 5.2 Neuroendocrine Tumor Drug Consumption by Regions
      • 5.3 North America Neuroendocrine Tumor Drug Market Analysis
        • 5.3.1 North America Neuroendocrine Tumor Drug Production
        • 5.3.2 North America Neuroendocrine Tumor Drug Revenue
        • 5.3.3 Key Manufacturers in North America
        • 5.3.4 North America Neuroendocrine Tumor Drug Import and Export
      • 5.4 Europe Neuroendocrine Tumor Drug Market Analysis
        • 5.4.1 Europe Neuroendocrine Tumor Drug Production
        • 5.4.2 Europe Neuroendocrine Tumor Drug Revenue
        • 5.4.3 Key Manufacturers in Europe
        • 5.4.4 Europe Neuroendocrine Tumor Drug Import and Export
      • 5.5 China Neuroendocrine Tumor Drug Market Analysis
        • 5.5.1 China Neuroendocrine Tumor Drug Production
        • 5.5.2 China Neuroendocrine Tumor Drug Revenue
        • 5.5.3 Key Manufacturers in China
        • 5.5.4 China Neuroendocrine Tumor Drug Import and Export
      • 5.6 Japan Neuroendocrine Tumor Drug Market Analysis
        • 5.6.1 Japan Neuroendocrine Tumor Drug Production
        • 5.6.2 Japan Neuroendocrine Tumor Drug Revenue
        • 5.6.3 Key Manufacturers in Japan
        • 5.6.4 Japan Neuroendocrine Tumor Drug Import and Export
      • 5.7 Southeast Asia Neuroendocrine Tumor Drug Market Analysis
        • 5.7.1 Southeast Asia Neuroendocrine Tumor Drug Production
        • 5.7.2 Southeast Asia Neuroendocrine Tumor Drug Revenue
        • 5.7.3 Key Manufacturers in Southeast Asia
        • 5.7.4 Southeast Asia Neuroendocrine Tumor Drug Import and Export
      • 5.8 India Neuroendocrine Tumor Drug Market Analysis
        • 5.8.1 India Neuroendocrine Tumor Drug Production
        • 5.8.2 India Neuroendocrine Tumor Drug Revenue
        • 5.8.3 Key Manufacturers in India
        • 5.8.4 India Neuroendocrine Tumor Drug Import and Export

      6 Neuroendocrine Tumor Drug Segment Market Analysis (by Type)

      • 6.1 Global Neuroendocrine Tumor Drug Production by Type
      • 6.2 Global Neuroendocrine Tumor Drug Revenue by Type
      • 6.3 Neuroendocrine Tumor Drug Price by Type

      7 Neuroendocrine Tumor Drug Segment Market Analysis (by Application)

      • 7.1 Global Neuroendocrine Tumor Drug Consumption by Application
      • 7.2 Global Neuroendocrine Tumor Drug Consumption Market Share by Application (2014-2019)

      8 Neuroendocrine Tumor Drug Major Manufacturers Analysis

      • 8.1 Eisai
        • 8.1.1 Eisai Neuroendocrine Tumor Drug Production Sites and Area Served
        • 8.1.2 Eisai Product Introduction, Application and Specification
        • 8.1.3 Eisai Neuroendocrine Tumor Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.1.4 Main Business and Markets Served
      • 8.2 Exelixis, Inc.
        • 8.2.1 Exelixis, Inc. Neuroendocrine Tumor Drug Production Sites and Area Served
        • 8.2.2 Exelixis, Inc. Product Introduction, Application and Specification
        • 8.2.3 Exelixis, Inc. Neuroendocrine Tumor Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.2.4 Main Business and Markets Served
      • 8.3 Foresee Pharmaceuticals, LLC
        • 8.3.1 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Production Sites and Area Served
        • 8.3.2 Foresee Pharmaceuticals, LLC Product Introduction, Application and Specification
        • 8.3.3 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.3.4 Main Business and Markets Served
      • 8.4 Hutchison MediPharma Limited
        • 8.4.1 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Production Sites and Area Served
        • 8.4.2 Hutchison MediPharma Limited Product Introduction, Application and Specification
        • 8.4.3 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.4.4 Main Business and Markets Served
      • 8.5 Intezyne, Inc
        • 8.5.1 Intezyne, Inc Neuroendocrine Tumor Drug Production Sites and Area Served
        • 8.5.2 Intezyne, Inc Product Introduction, Application and Specification
        • 8.5.3 Intezyne, Inc Neuroendocrine Tumor Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.5.4 Main Business and Markets Served
      • 8.6 INVENT Pharmaceuticals, Inc.
        • 8.6.1 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Production Sites and Area Served
        • 8.6.2 INVENT Pharmaceuticals, Inc. Product Introduction, Application and Specification
        • 8.6.3 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.6.4 Main Business and Markets Served
      • 8.7 Ipsen S.A.
        • 8.7.1 Ipsen S.A. Neuroendocrine Tumor Drug Production Sites and Area Served
        • 8.7.2 Ipsen S.A. Product Introduction, Application and Specification
        • 8.7.3 Ipsen S.A. Neuroendocrine Tumor Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.7.4 Main Business and Markets Served
      • 8.8 Jiangsu Hengrui Medicine Co., Ltd.
        • 8.8.1 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Production Sites and Area Served
        • 8.8.2 Jiangsu Hengrui Medicine Co., Ltd. Product Introduction, Application and Specification
        • 8.8.3 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.8.4 Main Business and Markets Served
      • 8.9 Karyopharm Therapeutics, Inc.
        • 8.9.1 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Production Sites and Area Served
        • 8.9.2 Karyopharm Therapeutics, Inc. Product Introduction, Application and Specification
        • 8.9.3 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.9.4 Main Business and Markets Served
      • 8.10 Lexicon Pharmaceuticals, Inc.
        • 8.10.1 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Production Sites and Area Served
        • 8.10.2 Lexicon Pharmaceuticals, Inc. Product Introduction, Application and Specification
        • 8.10.3 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.10.4 Main Business and Markets Served
      • 8.11 Midatech Pharma Plc .
      • 8.12 Millennium Pharmaceuticals, Inc.
      • 8.13 MolMed S.p.A.
      • 8.14 Northwest Biotherapeutics, Inc.
      • 8.15 Novartis AG
      • 8.16 OctreoPharm Sciences GmbH
      • 8.17 OXiGENE, Inc.

      9 Development Trend of Analysis of Neuroendocrine Tumor Drug Market

      • 9.1 Global Neuroendocrine Tumor Drug Market Trend Analysis
        • 9.1.1 Global Neuroendocrine Tumor Drug Market Size (Volume and Value) Forecast 2019-2025
      • 9.2 Neuroendocrine Tumor Drug Regional Market Trend
        • 9.2.1 North America Neuroendocrine Tumor Drug Forecast 2019-2025
        • 9.2.2 Europe Neuroendocrine Tumor Drug Forecast 2019-2025
        • 9.2.3 China Neuroendocrine Tumor Drug Forecast 2019-2025
        • 9.2.4 Japan Neuroendocrine Tumor Drug Forecast 2019-2025
        • 9.2.5 Southeast Asia Neuroendocrine Tumor Drug Forecast 2019-2025
        • 9.2.6 India Neuroendocrine Tumor Drug Forecast 2019-2025
      • 9.3 Neuroendocrine Tumor Drug Market Trend (Product Type)
      • 9.4 Neuroendocrine Tumor Drug Market Trend (Application)
      • 10.1 Marketing Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
      • 10.3 Neuroendocrine Tumor Drug Customers

      11 Market Dynamics

      • 11.1 Market Trends
      • 11.2 Opportunities
      • 11.3 Market Drivers
      • 11.4 Challenges
      • 11.5 Influence Factors

      12 Conclusion

        13 Appendix

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        The global Neuroendocrine Tumor Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
        This report focuses on Neuroendocrine Tumor Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Neuroendocrine Tumor Drug market size by analyzing historical data and future prospect.
        Regionally, this report categorizes the production, apparent consumption, export and import of Neuroendocrine Tumor Drug in North America, Europe, China, Japan, Southeast Asia and India.
        For each manufacturer covered, this report analyzes their Neuroendocrine Tumor Drug manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

        The following manufacturers are covered:
        Eisai
        Exelixis, Inc.
        Foresee Pharmaceuticals, LLC
        Hutchison MediPharma Limited
        Intezyne, Inc
        INVENT Pharmaceuticals, Inc.
        Ipsen S.A.
        Jiangsu Hengrui Medicine Co., Ltd.
        Karyopharm Therapeutics, Inc.
        Lexicon Pharmaceuticals, Inc.
        Midatech Pharma Plc .
        Millennium Pharmaceuticals, Inc.
        MolMed S.p.A.
        Northwest Biotherapeutics, Inc.
        Novartis AG
        OctreoPharm Sciences GmbH
        OXiGENE, Inc.

        Segment by Regions
        North America
        Europe
        China
        Japan
        Southeast Asia
        India

        Segment by Type
        mTOR protein inhibitors
        Tyrosine kinase 3 inhibitors
        Somatostatin receptor antagonists
        Growth hormone releasing factor antagonists
        Somatostatin receptor agonists
        Others

        Segment by Application
        Hospital
        Clinic
        Others

        Buy now